Volume | 786,601 |
|
|||||
News | - | ||||||
Day High | 172.213 | Low High |
|||||
Day Low | 169.22 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Insulet Corporation | PODD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
170.00 | 169.22 | 172.213 | 171.40 | 169.18 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,101 | 786,601 | $ 170.83 | $ 134,375,828 | - | 125.82 - 335.91 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:19:25 | 1 | $ 171.40 | USD |
Insulet (PODD) Options Flow Summary
Insulet Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.98B | 69.93M | - | 1.7B | 206.3M | 2.95 | 58.09 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Insulet News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PODD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 169.06 | 172.213 | 162.05 | 166.31 | 694,841 | 2.34 | 1.38% |
1 Month | 163.14 | 184.85 | 160.84 | 169.69 | 890,175 | 8.26 | 5.06% |
3 Months | 194.29 | 214.825 | 160.84 | 184.32 | 911,642 | -22.89 | -11.78% |
6 Months | 162.22 | 223.56 | 125.82 | 173.14 | 1,097,324 | 9.18 | 5.66% |
1 Year | 315.24 | 335.91 | 125.82 | 202.67 | 952,315 | -143.84 | -45.63% |
3 Years | 267.06 | 335.91 | 125.82 | 235.83 | 661,245 | -95.66 | -35.82% |
5 Years | 93.67 | 335.91 | 80.43 | 214.88 | 631,281 | 77.73 | 82.98% |
Insulet Description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide. |